The Company started as a research company in the early 2000s by Professor Lars Lidgren, with the vision of developing a synthetic product that could replace autograft and improve the quality of life for patients suffering from bone diseases.

  • 2019

    The randomized controlled trial CERTiFy “Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures” is published by Hofman et al in Journal of Bone and; Joint Surgery (American). The study confirms that patient reported outcomes and bone remodeling for CERAMENT BONE VOID FILLER are as good as autograft, but with less post-operative pain and blood loss.

    The largest analysis of Health Economic Data for a bone substitute is presented at EBJIS. The analysis included 25000 patients and compared the clinical and financial results of Nuffield Orthopedic Hospital’s care model including antibiotic eluting CERAMENT with the care provided at other hospitals in England.

    Ferguson et al. publish the paper “Radiographic and Histological Analysis of a Synthetic Bone Graft Substitute Eluting Gentamicin in the Treatment of Chronic Osteomyelitis” in the Journal of Bone and Joint infection. The study includes clinical biopsies and histology confirming bone remodeling of CERAMENT G in patients.

    The distribution agreement with Zimmer Biomet ends in May.

  • 2018

    CERTiFy study demonstrates CERAMENT®|BONE VOID FILLER is non-inferior to autograft in treating tibia plateau fracture defects

    BONESUPPORT sets up distribution network in USA

    CERAMENT®|G approved by Health Canada

    Product offering expanded by collaboration with Collagen Matrix Inc

    Emil Billbäck appointed as CEO

  • 2017

    FORTIFY study initiated for CERAMENT®|G*

    CERAMENT® V second generation launched with CERAMENT® | Delivery System and all components sterile

  • 2016

    FDA approval to initiate pivotal IDE clinical study of CERAMENT®|G* in USA

    Paper in Nature Scientific Reports demonstrates the potential of the CERAMENT® drug-eluting platform. Publication entitled ‘A Biphasic Calcium Sulphate Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone‘ (Raina, D et al).

    Publication in The Bone and Joint Journal demonstrates the utility of CERAMENT®|G in the management of chronic osteomyelitis. Paper entitled ‘Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite – A prospective series of 100 cases’ (McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96).

    Richard Davies appointed as CEO

    FY 2016 sales of SEK 105m (70% YoY growth)

  • 2015

    CE-mark for CERAMENT® V the first vancomycin antibiotic eluting injectable ceramic bone graft substitute

    CERAMENT®|BONE VOID FILLER and CERAMENT®|G* launched with new CERAMENT®|Delivery System

    PMA device pathway for CERAMENT®|G confirmed by FDA in the US

  • 2013

    CE-mark for CERAMENT®|G*, the first antibiotic eluting injectable ceramic bone graft substitute

  • 2012

    Distribution agreement with Biomet Inc for USA for CERAMENT®|BONE VOID FILLER

  • 2009


  • 2005

    CERAMENT®|BONE VOID FILLER is cleared to be marketed and sold in the US

  • 1999

    BONESUPPORT AB founded by Dr. Lars Lidgren, Professor in Orthopedic Surgery at Lund University and an internationally respected scientist

*Not available in the United States, for investigational use only
Not available in the United States